About Fibrin Glue
Fibrin glue is a derivative of human blood products and animals and it is mostly withdrawn from collective plasma and comprises of different quantities of purified and virally inactivated human proteins. Biological fibrin glue typically contains two basic components such as human thrombin and human fibrinogen, together with a fibrinolysis inhibitor to prevent fibrin degradation during the storage. The various features of fibrin glue are high surface adherence strength, high internal bond strength, and capability to improve tissue regeneration and clot formation.. Recently fibrin glue has received approval from the U.S. FDA and European Union for its use in spleen trauma, cardiovascular surgery, and for the closure of colostomies
Attributes | Details |
---|
Study Period | 2018-2030 |
Base Year | 2023 |
Unit | Value (USD Million) |
EThe companies are exploring the market by adopting expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Fibrin Glue market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.
Baxter (United States), Johnson & Johnson (United States), Dolphin Pharmaceutical Limited (India), 3S Corporation (United States), Cryolife(United States), Harvest Technologies(United States), CSL Behring(United States), Becton Dickinson(United States), Bayer (Germany), Shanghai RAAS (China) and STB Lifesaving Technologies (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Integra Lifesciences Holdings Corporation (United States) and Tricol Biomedical, Inc. (United States).
Segmentation Overview
AMA Research has segmented the market of Global Fibrin Glue market by Type (Hemostat, Adhesive and Sealant), Application (Hemostasis, Sealing, Tissue Gluing, Support for Wound Healing, Arein cardiac surgery, Burn to bleed and Pulmonary surgery) and Region.
On the basis of geography, the market of Fibrin Glue has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Type, the sub-segment i.e. Liquid will boost the Fibrin Glue market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Hospitals will boost the Fibrin Glue market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Influencing Trend:
Increasing government expenditure
Market Growth Drivers:
The increasing number of hospitals and rising healthcare awareness is one of the major driving factors of the growth and The increase in the number of surgeries
Challenges:
The requirement of skilled personnel
Restraints:
Rising healthcare costs and lack of reimbursements
Opportunities:
Improved healthcare in the emerging economies provides immense growth opportunities for the global fibrin glue market
Market Leaders and their expansionary development strategies
In May 2019, Ethicon, a Johnson & Johnson medical devices company, has agreed to acquired TachoSil Fibrin Sealant Patch from Japan-based Takeda Pharmaceutical for a cash consideration of around USD 400m. TachoSil is a surgical patch developed to enable safe and quick bleeding control. It is indicated for use with manual compression as an adjunct to haemostasis in cardiovascular and hepatic surgery.
In December 2019 Johnson & Johnson launched its Vistaseal fibrin sealant for managing bleeding during surgery. The sealant system is indicated as an adjunct to hemostasis for mild to moderate bleeding in adults undergoing surgery when control of bleeding by standard techniques (suture, ligature, cautery) are ineffective or impractical.
Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Fibrin Glue Manufacturer, Raw Material Suppliers, Government Regulatory and Research Organizations and End-Use Industry
About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.
Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.
The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.